PF3D7_1311800 details

You can find more information about M1-family alanyl aminopeptidase using the following links:

PlasmoDB - the Plasmodium genome resource
The TDR Targets Database

Subcellular Localization

PDB protein strucure

Affecting Drugs
Drug Name	PubMed Articles (year of publication)
((4-(1H-Pyrazol-1-yl)phenyl)(amino)methyl)phosphonic acid	Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions(2016)
(5S)-2-amino-5-[[(2S)-2-amino-2-phenyl-acetyl]-[2-anilino-1-(2-furyl)-2-oxo-ethyl]amino]-6-hydroxy-6-lambda3-oxidanylidyne-4-methyl-hexanoic acid	KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library(2017)
(Z)-2-(hydroxycarbamoyl)-3-phenyl-N-(4-phenylbutyl)prop-2-enamide	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents(2007)
(Z)-N-[(4-fluorophenyl)methyl]-2-(hydroxycarbamoyl)-3-phenyl-prop-2-enamide	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents(2007)
2-(2-(Bicyclo[2.2.1]heptan-2-yl)acetamido)-N-hydroxy-2-(3',4',5'-trifluoro-[1,1'-biphenyl]- 4-yl)acetamide	Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases(2019)
2-(4-bromophenyl)-2-(butoxymethylamino)ethanehydroxamic acid	Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions(2016)
2-(butoxymethylamino)-2-[4-(2,4,6-trifluorocyclohexa-2,4-dien-1-yl)phenyl]ethanehydroxamic acid	Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions(2016)
2-(hydroxycarbamoyl)-N-(1-naphthylmethyl)pentanamide	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents(2007)
2-(hydroxycarbamoyl)-N-[(5-phenoxycyclohexa-1,3-dien-1-yl)methyl]pentanamide	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents(2007)
2-[[(1-amino-3-phenyl-propyl)-hydroxy-phosphoryl]methyl]-3-(4-hydroxyphenyl)propanoic acid	Structural basis for the inhibition of the essential Plasmodium falciparum M1 neutral aminopeptidase(2009)
2-[[(1-Amino-4-phenylbutyl)hydroxyphosphinyl]-methyl]-3-(4-hydroxyphenyl)propionic Acid	Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials(2010)
2-[[(1-Amino-4-phenylbutyl)hydroxyphosphinyl]-methyl]-3-phenylpropionic Acid	Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials(2010)
2-amino-1-hydroxyphosphonates	Chemical target validation studies of aminopeptidase in malaria parasites using alpha-aminoalkylphosphonate and phosphonopeptide inhibitors(2008)
2-amino-N-[3-[4-[3-[(7-chloro-4-quinolyl)amino]propyl]piperazin-1-yl]propyl]-3-(hydroxyamino)-N-isobutyl-3-oxo-propanamide	Design, synthesis and antimalarial activity of novel, quinoline-based, zinc metallo-aminopeptidase inhibitors(2003)
2-benzyl-3-(hydroxyamino)-3-oxo-N-(4-phenylbutyl)propanamide	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents(2007)
2-benzyl-3-(hydroxyamino)-N-(o-tolylmethyl)-3-oxo-propanamide	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents(2007)
2-benzyl-N-[(4-fluorophenyl)methyl]-3-(hydroxyamino)-3-oxo-propanamide	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents(2007)
2-benzyl-N1-(4-fluorobenzyl)-N3-hydroxymalonamide	Structural characterization of plasmodial aminopeptidase: a combined molecular docking and QSAR-based in silico approaches(2019)
7-amino-4-phenyl-5,7,8,9-tetrahydro-6H-benzo[7]annulen-6-one	Selective inhibition of PfA-M1, over PfA-M17, by an amino-benzosuberone derivative blocks malaria parasites development in vitro and in vivo(2017)
7-amino-5,7,8,9-tetrahydro-6H-benzo[7]annulen-6-one	Aminobenzosuberone derivatives as PfA-M1 inhibitors: Molecular recognition and antiplasmodial evaluation(2020)
Alpha-aminoalkylphosphonates	Chemical target validation studies of aminopeptidase in malaria parasites using alpha-aminoalkylphosphonate and phosphonopeptide inhibitors(2008)
Amastatin	Plasmodium falciparum M1-aminopeptidase: a promising target for the development of antimalarials(2014)
and N-(1-(4-(1H-pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)pivalamide	Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions(2016)
Arginine fosfomycin	Plasmodium falciparum M1-aminopeptidase: a promising target for the development of antimalarials(2014)
Atovaquone	Modeling of human M1 aminopeptidases for in silico screening of potential Plasmodium falciparum alanine aminopeptidase (PfA-M1) specific inhibitors(2014)
Bdm14471	Structure-activity relationships and blood distribution of antiplasmodial aminopeptidase-1 inhibitors(2012)
Benzyl alcohol	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents(2007)
Bestatin	Roles for two aminopeptidases in vacuolar hemoglobin catabolism in Plasmodium falciparum(2007) Structural basis for the inhibition of the essential Plasmodium falciparum M1 neutral aminopeptidase(2009) Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials(2010) Synthesis of new (-)-bestatin-based inhibitor libraries reveals a novel binding mode in the S1 pocket of the essential malaria M1 metalloaminopeptidase(2011) The aminopeptidase inhibitor CHR-2863 is an orally bioavailable inhibitor of murine malaria(2012) Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum aminopeptidases, M1, M17 and M18(2015) KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library(2017) Mapping the Pathway and Dynamics of Bestatin Inhibition of the Plasmodium falciparum M1 Aminopeptidase PfA-M1(2018)
Bestatin methyl ester	Plasmodium falciparum M1-aminopeptidase: a promising target for the development of antimalarials(2014)
Chloroquine	Chloroquine mediates specific proteome oxidative damage across the erythrocytic cycle of resistant Plasmodium falciparum(2008)
Chr-2863	The aminopeptidase inhibitor CHR-2863 is an orally bioavailable inhibitor of murine malaria(2012) X-ray crystal structures of an orally available aminopeptidase inhibitor, Tosedostat, bound to anti-malarial drug targets PfA-M1 and PfA-M17(2015)
Chr-6768	The aminopeptidase inhibitor CHR-2863 is an orally bioavailable inhibitor of murine malaria(2012)
Deferoxamine	Inhibitors of the Plasmodium falciparum M17 Leucine Aminopeptidase()
E-64	Roles for two aminopeptidases in vacuolar hemoglobin catabolism in Plasmodium falciparum(2007)
Epiamastatin	Plasmodium falciparum M1-aminopeptidase: a promising target for the development of antimalarials(2014)
Fbs0701	Inhibitors of the Plasmodium falciparum M17 Leucine Aminopeptidase()
GNF-Pf-2389	A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases(2016)
GNF-Pf-2795	A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases(2016)
GNF-Pf-3024	A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases(2016)
GNF-Pf-3139	A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases(2016)
GNF-Pf-3890	A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases(2016)
GNF-Pf-4269	A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases(2016)
GNF-Pf-5492	A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases(2016)
Hydroxamate	Structure-activity relationships and blood distribution of antiplasmodial aminopeptidase-1 inhibitors(2012)
Malonic acid	Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents(2007) Plasmodium falciparum M1-aminopeptidase: a promising target for the development of antimalarials(2014)
MMV007228	Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum aminopeptidases, M1, M17 and M18(2015)
MMV007273	Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum aminopeptidases, M1, M17 and M18(2015)
MMV019241	Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum aminopeptidases, M1, M17 and M18(2015)
MMV020750	Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum aminopeptidases, M1, M17 and M18(2015)
MMV084434	Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum aminopeptidases, M1, M17 and M18(2015)
Mmv403679	Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum aminopeptidases, M1, M17 and M18(2015)
MMV665969	Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum aminopeptidases, M1, M17 and M18(2015)
MMV666022	Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum aminopeptidases, M1, M17 and M18(2015)
Mmv666023	Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum aminopeptidases, M1, M17 and M18(2015)
MMV666054	Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum aminopeptidases, M1, M17 and M18(2015)
N-(2-(hydroxyamino)-2-oxo-1-(4-(3,4,5-trifluorocyclohexyl)phenyl)ethyl)-3-methylbutanamide	Structure-based development of potent Plasmodium falciparum M1 and M17 aminopeptidase selective and dual inhibitors via S1'-region optimisation(2022)
N-[(2S,3R)-3-AMINO-2-HYDROXY-4-(4-METHOXYPHENYL) BUTANOYL]-L-LEUCINE	Improved QM/MM Linear-Interaction Energy Model for Substrate Recognition in Zinc-Containing Metalloenzymes(2016)
N-[3-[4-[3-[(7-chloro-4-quinolyl)amino]propyl]piperazin-1-yl]propyl]-2-(hydroxycarbamoyl)-N-isobutyl-4-methyl-pentanamide	Design, synthesis and antimalarial activity of novel, quinoline-based, zinc metallo-aminopeptidase inhibitors(2003)
N-[3-[4-[3-[(7-chloro-4-quinolyl)amino]propyl]piperazin-1-yl]propyl]-3-(hydroxyamino)-N-isobutyl-3-oxo-propanamide	Design, synthesis and antimalarial activity of novel, quinoline-based, zinc metallo-aminopeptidase inhibitors(2003)
Nitrobestatin	Plasmodium falciparum M1-aminopeptidase: a promising target for the development of antimalarials(2014)
Pepstatin	Roles for two aminopeptidases in vacuolar hemoglobin catabolism in Plasmodium falciparum(2007)
Peptide r1	Plasmodium falciparum M1-aminopeptidase: a promising target for the development of antimalarials(2014)
Phosphinate	Structural basis for the inhibition of the essential Plasmodium falciparum M1 neutral aminopeptidase(2009) Plasmodium falciparum M1-aminopeptidase: a promising target for the development of antimalarials(2014)
Pro-arg-fluoromethyl ketone	Roles for two aminopeptidases in vacuolar hemoglobin catabolism in Plasmodium falciparum(2007)
sMD simulation	Steered molecular dynamics simulations reveal critical residues for (un)binding of substrates, inhibitors and a product to the malarial M1 aminopeptidase(2018)
Substrate specificty suggested target	Fingerprinting the substrate specificity of M1 and M17 aminopeptidases of human malaria, Plasmodium falciparum(2012)
tert-butyl (1-(4-(1H-pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)carbamate	Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions(2016)
tert-butyl N-[1-(4-bromophenyl)-2-(hydroxyamino)-2-oxo-ethyl]carbamate	Localization and interactions of Plasmodium falciparum SWIB/MDM2 homologues(2016)
Tosedostat	Plasmodium falciparum M1-aminopeptidase: a promising target for the development of antimalarials(2014) Inhibitors of the Plasmodium falciparum M17 Leucine Aminopeptidase() X-ray crystal structures of an orally available aminopeptidase inhibitor, Tosedostat, bound to anti-malarial drug targets PfA-M1 and PfA-M17(2015)